Cargando…
Sonidegib for the Treatment of Advanced Basal Cell Carcinoma
Basal cell carcinoma (BCC) accounts for almost 80% of skin cancers, and its healthcare workload burden is substantial within dermatology departments. Although most BCCs are small, well-defined tumors amenable of surgery or conservative procedures, in a small proportion of patients, BCCs can progress...
Autores principales: | Brancaccio, Gabriella, Pea, Federico, Moscarella, Elvira, Argenziano, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662670/ https://www.ncbi.nlm.nih.gov/pubmed/33194718 http://dx.doi.org/10.3389/fonc.2020.582866 |
Ejemplares similares
-
Sonidegib treatment in patients with locally advanced basal cell carcinoma
por: Villani, Alessia, et al.
Publicado: (2022) -
Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma
por: Villani, Alessia, et al.
Publicado: (2020) -
Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas
por: Villani, Alessia, et al.
Publicado: (2022) -
The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area
por: Villani, Alessia, et al.
Publicado: (2023) -
Effective systemic treatment of advanced periocular basal cell carcinoma with sonidegib
por: Rokohl, Alexander C., et al.
Publicado: (2021)